New combo tackles Hard-to-Treat breast cancer

NCT ID NCT04360941

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times

Summary

This early-stage study tests two drugs, palbociclib and avelumab, together for people with a specific type of advanced breast cancer (AR+ triple negative). The main goals are to find the safest doses and see if the combination can shrink tumors. About 45 participants will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ERΑ+ BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Addenbrooke's Hospital Cambridge University Hospitals NHS Foundation Trust

    RECRUITING

    Cambridge, CB2 0QQ, United Kingdom

  • Barts Cancer Institute

    RECRUITING

    London, EC1M 6BQ, United Kingdom

  • Beatson West of Scotland Cancer Centre

    RECRUITING

    Glasgow, G12 0YN, United Kingdom

  • Hope Clinical Trials Cancer Centre

    RECRUITING

    Leicester, LE1 5WW, United Kingdom

  • Nottingham University Hospital

    ACTIVE_NOT_RECRUITING

    Nottingham, NG5 1PB, United Kingdom

  • Royal Marsden NHS Foundation Trust

    RECRUITING

    London, SW3 6JJ, United Kingdom

  • The Christie NHS Foundation Trust

    RECRUITING

    Manchester, Greater Manchester, M20 4BX, United Kingdom

  • University College London Hospitals NHS Foundation Trust

    RECRUITING

    London, W1T 7HA, United Kingdom

  • Weston Park Hospital

    RECRUITING

    Sheffield, S10 2SJ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.